The latest price target for Aerovate Therapeutics (NASDAQ:AVTE) was reported by Evercore ISI Group on June 18, 2024. The analyst firm set a price target for $2.00 expecting AVTE to fall to within 12 months (a possible -20.96% downside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Aerovate Therapeutics (NASDAQ:AVTE) was provided by Evercore ISI Group, and Aerovate Therapeutics downgraded their in-line rating.

The last upgrade for Aerovate Therapeutics Inc happened on December 6, 2022 when BTIG raised their price target to $27. BTIG previously had a neutral for Aerovate Therapeutics Inc.

The last downgrade for Aerovate Therapeutics Inc happened on June 18, 2024 when Evercore ISI Group changed their price target from $27 to $2 for Aerovate Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aerovate Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aerovate Therapeutics was filed on June 18, 2024 so you should expect the next rating to be made available sometime around June 18, 2025.

While ratings are subjective and will change, the latest Aerovate Therapeutics (AVTE) rating was a downgraded with a price target of $27.00 to $2.00. The current price Aerovate Therapeutics (AVTE) is trading at is $2.53, which is out of the analyst’s predicted range.